How has ANI Pharmaceuticals's equity securities (FV-NI) - cost basis changed year-over-year?

ANI Pharmaceuticals's equity securities (FV-NI) - cost basis increased by 176.4% year-over-year, from $5.39M to $14.89M.

ANI Pharmaceuticals ANIP Equity Securities (FV-NI) - Cost Basis

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Market cap$1.88B+18.3%

Enterprise value$1.87B+5.8%

P/E20.4×—

P/S2×-0.3×

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is ANI Pharmaceuticals's equity securities (FV-NI) - cost basis?: ANI Pharmaceuticals (ANIP) reported equity securities (FV-NI) - cost basis of $14.89M in Q1 2026.
How has ANI Pharmaceuticals's equity securities (FV-NI) - cost basis changed year-over-year?: ANI Pharmaceuticals's equity securities (FV-NI) - cost basis increased by 176.4% year-over-year, from $5.39M to $14.89M.